Stephen H. Thorne, PhD

Stephen H. Thorne, PhD


Office: 1A-106 HCC, 5117 Centre Avenue

Pittsburgh, PA 15213

Ph: 412-623-4896

Fax: 412-623-2525


  • Ph.D. - Imperial College, London, UK (1998)
  • Postdoc - Surrey University, UK (1998-2000)
  • Postdoc - Cancer Research UK, London, UK (2000-2002)
  • Postdoc - Veteran's Affairs Hospital, Palo Alto, CA (2002-2003)
  • Postdoc - Stanford University, Stanford, CA (2003-2007)

Academic Affiliation

  • Assistant Professor, Department of Surgery, University of Pittsburgh School of Medicine
  • Assistant Professor, Department of Immunology, University of Pittsburgh School of Medicine

About Research

  • Designing and testing attenuated strains of vaccinia virus to act as oncolytic agents for the treatment of cancer
  • Testing of transgenes expressed from oncolytic vaccinia virus strains;
especially effects of immunomodulatory genes and effects of controlling gene function
  • Effects of combining oncolytic viruses with immune cells as combination cancer therapies; especially the use of immune cells as carrier vehicles to deliver viruses to tumors
  • Use of Phosflow to examine host cell-pathogen interactions
  • Use of pre-clinical imaging (especially optical imaging) to non-invasively examine molecular events in vivo; especially in context of biological therapies for cancer and immune function

Selected Publications

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a multi-mechanistic oncoloytic vaccinia virus. PLOS Med, in press. 2007.

Thorne SH, Hwang TH, O’Gorman BE, Bartlett DL, Sei S, Adiata F,
Brown C, Werier J, Jo JH, Lee DE, Wang Y, Bell J, Kirn DH. Rational strain selection and engineering creates a broad spectrum systemically effective oncolytic poxvirus JX-963. J Clin Invest 117(11):3350-3358. 2007.

Thorne SH, Contag CH. Combining immune cell and viral therapy for the treatment of cancer. Cell Mol Life Sci 64(12): 1449-51. 2007.

Thorne SH. Strategies to achieve systemic delivery of therapeutic cells and microbes to tumors. Expert Opin Biol Ther 7(1): 41-51. 2007.

Au T, Thorne S, Korn M, Sze D, Kirn D, Reid T. Minimal hepatic
toxicity of Onyx-015: Spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 14(2):139-150. 2007.

PubMed Link